Terns Pharmaceuticals Inc (NASDAQ: TERN) is a biotech developing small-molecule therapies for non-alcoholic steatohepatitis (NASH), obesity, and cardiometabolic diseases. With multiple clinical programs targeting liver and metabolic disorders, Terns offers traders speculative exposure to high-prevalence, underserved disease areas with blockbuster potential.
Τελευταία άρθρα για μετοχές